161 related articles for article (PubMed ID: 36815621)
1. Clinical management of stage III non-small cell lung cancer in India: An expert consensus statement.
Batra U; Prabhash K; Agarwal JP; Darlong L; Munshi A; Penumadu P; Thangakunam B; Bansal A
Asia Pac J Clin Oncol; 2023 Dec; 19(6):606-617. PubMed ID: 36815621
[TBL] [Abstract][Full Text] [Related]
2. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.
J Clin Oncol; 1997 Aug; 15(8):2996-3018. PubMed ID: 9256144
[TBL] [Abstract][Full Text] [Related]
3. A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study.
Isla D; Felip E; Garrido P; Insa A; Majem M; Remon J; Trigo JM; de Castro J
Clin Transl Oncol; 2023 Jan; 25(1):283-291. PubMed ID: 36168085
[TBL] [Abstract][Full Text] [Related]
4. Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists.
Dudani S; Leighl NB; Ho C; Pantarotto JR; Zhu X; Zhang T; Wheatley-Price P
Lung Cancer; 2016 Apr; 94():74-80. PubMed ID: 26973210
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and real-world evidence for stage III non-small cell lung cancer in Central and Eastern Europe.
Zemanova M; Jakopovic M; Stanic K; Łazar-Poniatowska M; Vrankar M; Rusu P; Ciuleanu T; Radosavljevic D; Bogos K; Nawrocki S
Radiol Oncol; 2020 Oct; 54(4):447-454. PubMed ID: 33048837
[TBL] [Abstract][Full Text] [Related]
6. Stage III Non-small Cell Lung Cancer: A UK National Survey of Practice.
Evison M; Edwards J; McDonald F; Popat S
Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):527-536. PubMed ID: 32216979
[TBL] [Abstract][Full Text] [Related]
7. Treatment Decision Drivers in Stage III Non-Small-Cell Lung Cancer: Outcomes of a Web-Based Survey of Oncologists in the United States.
Cotarla I; Boron ML; Cullen SL; Spinner DS; Faulkner EC; Carroll MC; Shah S; Yagui-Beltran A
JCO Oncol Pract; 2020 Oct; 16(10):e1232-e1242. PubMed ID: 32552457
[TBL] [Abstract][Full Text] [Related]
8. Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach.
Bruni A; Giaj-Levra N; Ciammella P; Maragna V; Ferrari K; Bonti V; Grossi F; Greco S; Greco C; Borghetti P; Franceschini D; Capelletto E; Perna M; Banna G; Vagge S; Baldini E; Bria E; Botti A; Tiseo M; Paci M; Taraborrelli M; Poletti V; Granone P; Ricardi U; Novello S; Scotti V
PLoS One; 2019; 14(11):e0224027. PubMed ID: 31721773
[TBL] [Abstract][Full Text] [Related]
9. Multi-disciplinary approach for the management of non-metastatic non-small cell lung cancer in the Middle East and Africa: Expert panel recommendations.
Göker E; Altwairgi A; Al-Omair A; Tfayli A; Black E; Elsayed H; Selek U; Koegelenberg C
Lung Cancer; 2021 Aug; 158():60-73. PubMed ID: 34119934
[TBL] [Abstract][Full Text] [Related]
10. Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee.
Califano R; Karamouzis MV; Banerjee S; de Azambuja E; Guarneri V; Hutka M; Jordan K; Kamposioras K; Martinelli E; Corral J; Postel-Vinay S; Preusser M; Porcu L; Torri V
Lung Cancer; 2014 Jul; 85(1):74-80. PubMed ID: 24746176
[TBL] [Abstract][Full Text] [Related]
11. Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process.
Tankel J; Spicer J; Chu Q; Fiset PO; Kidane B; Leighl NB; Joubert P; Maziak D; Palma D; McGuire A; Melosky B; Snow S; Bahig H; Blais N
Curr Oncol; 2023 Dec; 30(12):10363-10384. PubMed ID: 38132389
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
13. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP.
Ospina AV; Bolufer Nadal S; Campo-Cañaveral de la Cruz JL; González Larriba JL; Macía Vidueira I; Massutí Sureda B; Nadal E; Trancho FH; Álvarez Kindelán A; Del Barco Morillo E; Bernabé Caro R; Bosch Barrera J; Calvo de Juan V; Casal Rubio J; de Castro J; Cilleruelo Ramos Á; Cobo Dols M; Dómine Gómez M; Figueroa Almánzar S; Garcia Campelo R; Insa Mollá A; Jarabo Sarceda JR; Jiménez Maestre U; López Castro R; Majem M; Martinez-Marti A; Martínez Téllez E; Sánchez Lorente D; Provencio M
Clin Transl Oncol; 2024 Jul; 26(7):1647-1663. PubMed ID: 38530556
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
[TBL] [Abstract][Full Text] [Related]
15. Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer.
Majem M; Hernández-Hernández J; Hernando-Trancho F; Rodríguez de Dios N; Sotoca A; Trujillo-Reyes JC; Vollmer I; Delgado-Bolton R; Provencio M
Clin Transl Oncol; 2020 Jan; 22(1):21-36. PubMed ID: 31172444
[TBL] [Abstract][Full Text] [Related]
16. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
Brahmer JR; Govindan R; Anders RA; Antonia SJ; Sagorsky S; Davies MJ; Dubinett SM; Ferris A; Gandhi L; Garon EB; Hellmann MD; Hirsch FR; Malik S; Neal JW; Papadimitrakopoulou VA; Rimm DL; Schwartz LH; Sepesi B; Yeap BY; Rizvi NA; Herbst RS
J Immunother Cancer; 2018 Jul; 6(1):75. PubMed ID: 30012210
[TBL] [Abstract][Full Text] [Related]
17. New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists - INTERACTION group.
Catania C; Filippi AR; Sangalli C; Piperno G; Russano M; Greco C; Scotti V; Proto C; Bennati C; Di Pietro Paolo M; Platania A; Olmetto E; Agustoni F; Teodorani N; Agbaje V; Russo A
Crit Rev Oncol Hematol; 2023 Oct; 190():104108. PubMed ID: 37633350
[TBL] [Abstract][Full Text] [Related]
18. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Howington JA; Blum MG; Chang AC; Balekian AA; Murthy SC
Chest; 2013 May; 143(5 Suppl):e278S-e313S. PubMed ID: 23649443
[TBL] [Abstract][Full Text] [Related]
19. Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases.
Ponce S; Bruna J; Juan O; López R; Navarro A; Ortega AL; Puente J; Verger E; Bartolomé A; Nadal E
Crit Rev Oncol Hematol; 2019 Jun; 138():190-206. PubMed ID: 31092376
[TBL] [Abstract][Full Text] [Related]
20. ASTRO Radiation Therapy Summary of the ASCO Guideline on Management of Stage III Non-Small Cell Lung Cancer.
Simone CB; Bradley J; Chen AB; Daly ME; Louie AV; Robinson CG; Videtic GMM; Rodrigues G
Pract Radiat Oncol; 2023; 13(3):195-202. PubMed ID: 37080641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
